Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019

Vivoryon Therapeutics to Attend and Present at Investor Conferences
in November 2019

HALLE (SAALE), Germany, 4 November 2019 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), announced today that the company is scheduled to attend and present at upcoming conferences in November.
 

(1) BIO Europe
November 11-13, 2019; Hamburg Messe, Hamburg, Germany
Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, to host meetings
Dr. Dauer to present on Monday, November 11, 2019; at 3:30pm CET, in Hall B1, Room 6 on Level 1
 

(2) Deutsches Eigenkapitalforum
November 25-27, 2019; Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt, Germany
Dr. Ulrich Dauer, CEO, to host meetings and present on Monday November 25, 2019; at 3:00pm CET in Room Oslo
 

###
 

For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: [email protected]

Trophic Communications
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 176 2103 7191
Email: [email protected] / [email protected]

MC Services AG
Anne Hennecke / Susanne Kutter
Tel: +49 (0) 211 529 252 27
Email: [email protected]

About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. (www.vivoryon.com)

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.